Pharmacoeconomic analysis of erlotinib as second-line treatment of advanced non-small cell lung cancer in Taiwan

被引：0
|
作者：
Hsia, T. [1 ]
Chang, G. [2 ]
Chen, Y. [3 ]
Lin, M. [4 ]
Su, W. [5 ]
Tsai, C. [3 ,6 ]
Tsai, C. [3 ,6 ]
Yang, L. [6 ]
机构：
[1] China Med Univ Hosp, Dept Pulm Med, Taichung, Taiwan
[2] Taichung Vet Gen Hosp, Dept Pulm Med, Taichung, Taiwan
[3] Vet Gen Hosp, Chest Dept, Taipei, Taiwan
[4] Chang Guang Mem Hosp, Dept Pulm & Crit Care Med, Kaohsiung, Taiwan
[5] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
[6] Roche Prod Ltd, Dept Pharma, Taipei, Taiwan
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71386-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6558
引用
收藏
页码：375 / 375
页数：1
相关论文
共 50 条
  • [41] Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
    Fragoulakis, V. F.
    Pallis, A. G.
    Kaitelidou, D. K.
    Maniadakis, N. M.
    Georgoulias, V. G.
    LUNG CANCER-TARGETS AND THERAPY, 2012, 3 : 43 - 51
  • [42] ERLOTINIB AS SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): ECONOMIC MODELING (EM) RESULTS
    Santos, E. A., V
    Buschinelli, C. T.
    Ferracini, M.
    Pepe, C.
    Estanislao, M.
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [43] BIOMARKERS OF TORCH TRIAL ON FIRST-LINE ERLOTINIB FOLLOWED BY SECOND-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
    Tsao, M. S.
    Gallo, C.
    Saieg, M.
    Santos, G. D. C.
    Gebbia, V.
    Perrone, F.
    Butts, C.
    Ciardiello, F.
    Feld, R.
    Gridelli, C.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S59 - S59
  • [44] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [45] Review of erlotinib in the treatment of advanced non-small cell lung cancer
    Ganjoo, Kristen N.
    Wakelee, Heather
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (04): : 335 - 346
  • [46] Switch Maintenance versus Second-Line Treatment in Non-small Cell Lung Cancer
    Rossi, Antonio
    Torri, Valter
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (07) : 1298 - 1298
  • [47] Evaluation of second-line treatment options in non-small cell lung cancer - Introduction
    Scagliotti, GV
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S1 - S2
  • [48] ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATMENT
    Goncalves, Ivone M.
    Monteiro, Regina
    Neves, Sofia
    Conde, Sara
    Campainha, Sergio
    Parente, Barbara
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1298 - S1298
  • [49] Cisplatin combination regimen in the second-line treatment of non-small cell lung cancer
    Altundag, O.
    Mertsoylu, H.
    Akcall, Z.
    Sakalli, H.
    Ozyilkan, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer
    Choong, Nicholas W.
    Mazcer, Ann M.
    Hoffman, Philip C.
    Rudin, Charles M.
    Winegarden, Jerome D., III
    Villano, J. Lee
    Kozloff, Mark
    Wade, James L., III
    Sciortino, David F.
    Szeto, Livia
    Vokes, Everett E.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (03) : 245 - 251
12345